Our findings demonstrate that CPTD effectively mitigates hepatic inflammation post-APAP injury by significantly suppressing both NF-κB pathway activation and NLRP3 upregulation, thereby underscoring CPTD's potential to reduce the incidence of systemic inflammatory response syndrome (SIRS) following APAP damage (Figure S26A-C, Supporting Information). Here, NLRP3 is linked to systemic inflammatory response syndrome.